These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34175901)

  • 1. DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.
    Toksvang LN; Grell K; Nersting J; Degn M; Nielsen SN; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Lepik K; Vaitkevičienė G; Griškevičius L; Quist-Paulsen P; Vora A; Moorman AV; Murdy D; Zimmermann M; Möricke A; Bostrom B; Joshi J; Hjalgrim LL; Dalhoff KP; Als-Nielsen B; Schmiegelow K
    Leukemia; 2022 Jan; 36(1):33-41. PubMed ID: 34175901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
    Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.
    Tulstrup M; Grosjean M; Nielsen SN; Grell K; Wolthers BO; Wegener PS; Jonsson OG; Lund B; Harila-Saari A; Abrahamsson J; Vaitkeviciene G; Pruunsild K; Toft N; Holm M; Hulegårdh E; Liestøl S; Griskevicius L; Punab M; Wang J; Carroll WL; Zhang Z; Dalgaard MD; Gupta R; Nersting J; Schmiegelow K
    Leukemia; 2018 Dec; 32(12):2527-2535. PubMed ID: 30201983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia.
    Larsen RH; Hjalgrim LL; Degn M; Nersting J; Als-Nielsen B; Grell K; Schmiegelow K
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):53-60. PubMed ID: 33754188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
    Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K
    BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia.
    Larsen RH; Utke Rank C; Grell K; Nørgaard Møller L; Malthe Overgaard U; Kampmann P; Nersting J; Degn M; Nygaard Nielsen S; Holst H; Klug Albertsen B; Skov Wehner P; Thude Callesen M; Kanerva J; Leth Frandsen T; Als-Nielsen B; Lyngsie Hjalgrim L; Schmiegelow K
    Haematologica; 2021 Nov; 106(11):2824-2833. PubMed ID: 34047177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy.
    Warren DJ; Andersen A; Slørdal L
    Cancer Res; 1995 Apr; 55(8):1670-4. PubMed ID: 7712473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India.
    Mishra V; Jain S; Anand V; Malhotra P; Tejwani N; Kapoor G
    Pediatr Hematol Oncol; 2023; 40(6):517-528. PubMed ID: 36930957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience.
    Ifversen M; Turkiewicz D; Marquart HV; Winiarski J; Buechner J; Mellgren K; Arvidson J; Rascon J; Körgvee LT; Madsen HO; Abrahamsson J; Lund B; Jonsson OG; Heilmann C; Heyman M; Schmiegelow K; Vettenranta K
    Br J Haematol; 2019 Mar; 184(6):982-993. PubMed ID: 30680711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
    Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
    Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.
    Ju HY; Lee JW; Cho HW; Hyun JK; Ma Y; Yi ES; Yoo KH; Sung KW; Choi R; Koo HH; Lee SY
    PLoS One; 2021; 16(1):e0245667. PubMed ID: 33481917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
    Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
    BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.
    Chen L; Yan HX; Liu XW; Chen WX
    Medicine (Baltimore); 2020 May; 99(18):e20082. PubMed ID: 32358392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study.
    Thastrup M; Marquart HV; Levinsen M; Grell K; Abrahamsson J; Albertsen BK; Frandsen TL; Harila-Saari A; Lähteenmäki PM; Niinimäki R; Pronk CJ; Ulvmoen A; Vaitkevičienė G; Taskinen M; Schmiegelow K;
    Leukemia; 2020 Feb; 34(2):336-346. PubMed ID: 31534171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia.
    Evensen NA; Madhusoodhan PP; Meyer J; Saliba J; Chowdhury A; Araten DJ; Nersting J; Bhatla T; Vincent TL; Teachey D; Hunger SP; Yang J; Schmiegelow K; Carroll WL
    Haematologica; 2018 May; 103(5):830-839. PubMed ID: 29449434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of Thioguanine in DNA Using Liquid Chromatography-Tandem Mass Spectrometry for Routine Thiopurine Drug Monitoring in Patients With Pediatric Acute Lymphoblastic Leukemia.
    Choi R; Chun MR; Park J; Lee JW; Ju HY; Cho HW; Hyun JK; Koo HH; Yi ES; Lee SY
    Ann Lab Med; 2021 Mar; 41(2):145-154. PubMed ID: 33063676
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Dreisig K; Brünner ED; Marquart HV; Helt LR; Nersting J; Frandsen TL; Jonsson OG; Taskinen M; Vaitkeviciene G; Lund B; Abrahamsson J; Lepik K; Schmiegelow K
    Pediatr Hematol Oncol; 2021 Apr; 38(3):227-238. PubMed ID: 33205673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.